Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Cancer Journal (Sudbury, Mass.)|October 13, 2006
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigationsEdward B Rubenstein, Barbara S Slusher, Camilo Rojas, et al.
Critical Reviews in Oncology/Hematology|December 1, 2020
Efficacy of intravenous NEPA, a fixed NK<sub>1</sub>/5-HT<sub>3</sub> receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studiesMatti Aapro, Rudolph M Navari, Eric Roeland, et al.
Journal of Pain and Symptom Management|August 30, 2005
Symptomatic treatment of infections in patients with advanced cancer receiving hospice careRaquel E Reinbolt, Allison M Shenk, Patrick H White, et al.
The Journal of Community and Supportive Oncology|May 7, 2016
Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomitingRudolph M Navari, Cindy K Nagy, Jennifer Le-Rademacher, et al.
Journal of Pain and Symptom Management|May 3, 2003
Antimicrobial use in patients with advanced cancer receiving hospice carePatrick H White, Heather L Kuhlenschmidt, Benjamin G Vancura, et al.
Cancer Medicine|May 24, 2018
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapyRudolph M Navari, Bernardo L Rapoport, Dan Powers, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 6, 2016
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomitingLawrence H Einhorn, Bernardo Rapoport, Rudolph M Navari, et al.
Blood|September 23, 2010
An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemiaFrancis J Castellino, Deborah L Donahue, Rudolph M Navari, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 7, 2021
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patientsRonald Chow, Leonard Chiu, Jørn Herrstedt, et al.
Future Oncology (London, England)|April 21, 2021
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysisRudolph M Navari, Gary Binder, Erminio Bonizzoni, et al.
Pageof 8